A cohort of 34 patients diagnosed of non-small cell lung cancer with ALK translocation were retrospectively analyzed in our center between 2008-2018. Baseline demographics characteristics were described. OS was calculated as the main objective.Patients were followed a median of 47 months (IQR 30-203). Median age was 59 years (IQR 36-83), being 47% male and 53% female. 44% were never smokers and 58% had any comorbidities. At diagnosis, 83% were symptomatic and the most frequent metastases were bone ones (32%). Complete baseline characteristics are shown in Table 1. Median OS was 32 months (IQR 15-78). 1-year, 2-year and 3- year survival was 75%, 69% 49.9% respectively. The ALK translocation and targeted treatments have led to a dramatic improvement in overall survival in clinical trials confirmed in our series. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.2393
Authors: B. Núñez-García, R. Gómez-Bravo, J.C. Sánchez, B. Cantos, M. Méndez, A.M. Morito, M. Blanco, V. Calvo, M. Provencio
